|
Treatment
|
PC-3% survival
|
FR generated% of control
|
LXA4 levels% of control
|
IL-6% of control
|
TNF-α% of control
|
|---|
|
Control
|
100 ± 1.86
|
100 ± 2.09
|
100 ± 2.60
|
100 ± 0.07
|
100 ± 6.34
|
|
LA 50 μM
|
105.00 ± 1.81*
|
104.31 ± 6.33*
|
56.00 ± 6.61***
|
67.06 ± 6.11**
|
53.75 ± 6.67***
|
|
LA 150 μM
|
95.00 ± 4.62*
|
102.65 ± 6.77*
|
72.00 ± 4.00**
|
71.18 ± 4.58**
|
71.25 ± 3.97**
|
|
GLA 25 μM
|
88.61 ± 4.39*
|
68.49 ± 3.35**
|
187.49 ± 2.11***
|
158.71 ± 9.66***
|
137.00 ± 3.94**
|
|
GLA 50 μM
|
82.53 ± 3.72**
|
74.67 ± 2.34**
|
179.34 ± 0.79***
|
148.57 ± 8.14***
|
148.81 ± 4.64***
|
|
GLA 75 μM
|
67.74 ± 3.81***
|
58.97 ± 5.11***
|
200.20 ± 2.94***
|
174.32 ± 7.32***
|
259.95 ± 6.95***
|
|
AA 50 μM
|
80.35 ± 1.21**
|
55.81 ± 2.99***
|
108.90 ± 0.39*
|
100.66 ± 5.24
|
73.22 ± 0.91**
|
|
AA 100 μM
|
60.08 ± 4.04***
|
76.32 ± 3.80**
|
99.17 ± 1.07
|
98.22 ± 1.32
|
65.50 ± 1.28**
|
|
ALA 50 μM
|
93.14 ± 1.66*
|
112.27 ± 6.82*
|
56.41 ± 5.44***
|
57.14 ± 4.58***
|
75.00 ± 3.90**
|
|
ALA150μM
|
70.59 ± 1.51**
|
160.86 ± 7.10***
|
48.72 ± 6.92***
|
45.71 ± 7.70***
|
83.75 ± 6.54**
|
|
EPA 50 μM
|
83.36 ± 6.65**
|
90.84 ± 6.30*
|
88.50 ± 0.75*
|
97.77 ± 2.13
|
80.41 ± 3.29**
|
|
EPA 100 μM
|
77.83 ± 5.55**
|
76.98 ± 4.97**
|
89.54 ± 1.22*
|
101.33 ± 5.59
|
81.13 ± 1.00**
|
|
DHA 50 μM
|
88.94 ± 6.91*
|
80.99 ± 2.88**
|
81.43 ± 1.09**
|
67.64 ± 1.95**
|
69.14 ± 2.85**
|
|
DHA100μM
|
75.88 ± 3.55**
|
67.00 ± 6.24**
|
76.84 ± 0.69**
|
57.71 ± 2.78***
|
66.69 ± 1.60**
|
- *P < 0.05, **P < 0.01, ***P < 0.001 compared to control.
